Back to Search
Start Over
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
- Source :
-
American journal of hematology [Am J Hematol] 2020 Apr; Vol. 95 (4), pp. E95-E98. Date of Electronic Publication: 2020 Jan 23. - Publication Year :
- 2020
- Subjects :
- Aged
Aged, 80 and over
Clinical Trials as Topic statistics & numerical data
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Logistic Models
Male
Middle Aged
Myeloid Differentiation Factor 88 genetics
Prognosis
Progression-Free Survival
Proportional Hazards Models
Prospective Studies
Treatment Outcome
Waldenstrom Macroglobulinemia drug therapy
Waldenstrom Macroglobulinemia mortality
beta 2-Microglobulin analysis
Mutation
Proteasome Inhibitors therapeutic use
Receptors, CXCR4 genetics
Waldenstrom Macroglobulinemia genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1096-8652
- Volume :
- 95
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- American journal of hematology
- Publication Type :
- Academic Journal
- Accession number :
- 31943341
- Full Text :
- https://doi.org/10.1002/ajh.25730